CN116421679A - Traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection and preparation method thereof Download PDFInfo
- Publication number
- CN116421679A CN116421679A CN202310155961.9A CN202310155961A CN116421679A CN 116421679 A CN116421679 A CN 116421679A CN 202310155961 A CN202310155961 A CN 202310155961A CN 116421679 A CN116421679 A CN 116421679A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- cerebral hemorrhage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 206010008111 Cerebral haemorrhage Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 36
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 16
- 210000000582 semen Anatomy 0.000 claims abstract description 16
- 241000132012 Atractylodes Species 0.000 claims abstract description 14
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 13
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 244000197580 Poria cocos Species 0.000 claims abstract description 12
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 12
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 10
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 10
- 235000020224 almond Nutrition 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 9
- 241001547125 Fritillaria thunbergii Species 0.000 claims abstract description 9
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 9
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 9
- 235000006533 astragalus Nutrition 0.000 claims abstract description 9
- 240000004980 Rheum officinale Species 0.000 claims abstract description 7
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 7
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 241000219061 Rheum Species 0.000 claims description 8
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 8
- 240000000249 Morus alba Species 0.000 claims description 7
- 235000008708 Morus alba Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 241001522129 Pinellia Species 0.000 claims description 5
- 241000605445 Anemarrhena asphodeloides Species 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 4
- 241000935235 Fritillaria meleagris Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 244000018633 Prunus armeniaca Species 0.000 claims description 4
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 4
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 241000675108 Citrus tangerina Species 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 3
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 abstract description 27
- 230000008901 benefit Effects 0.000 abstract description 6
- 210000004072 lung Anatomy 0.000 description 59
- 210000000038 chest Anatomy 0.000 description 38
- 206010061218 Inflammation Diseases 0.000 description 19
- 208000032376 Lung infection Diseases 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- 210000000952 spleen Anatomy 0.000 description 18
- 206010062717 Increased upper airway secretion Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 208000026435 phlegm Diseases 0.000 description 17
- 208000032843 Hemorrhage Diseases 0.000 description 14
- 206010036790 Productive cough Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 206010037660 Pyrexia Diseases 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- 108010048233 Procalcitonin Proteins 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000002151 Pleural effusion Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010006145 Brain stem haemorrhage Diseases 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 208000003443 Unconsciousness Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 208000034059 Basal Ganglia Hemorrhage Diseases 0.000 description 2
- 241000197194 Bulla Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010058939 Thalamus haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000009516 brain contusion Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013185 thoracic computed tomography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating cerebral hemorrhage complicated with pulmonary infection and a preparation method thereof, belonging to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following components in parts by weight: 15-25 parts of astragalus membranaceus, 10-20 parts of codonopsis pilosula, 10-20 parts of bighead atractylodes rhizome, 10-15 parts of poria cocos, 10-15 parts of scutellaria baicalensis, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of cortex mori, 8-12 parts of fritillaria thunbergii, 10-15 parts of rhizoma pinellinae praeparata, 10-15 parts of pericarpium citri reticulatae, 4-8 parts of semen trichosanthis, 4-8 parts of almond, 6-12 parts of raw rheum officinale, 10-15 parts of magnolia officinalis, 5-15 parts of immature bitter orange and 4-8 parts of liquorice. The traditional Chinese medicine composition can be matched with western medicine conventional treatment to treat patients with cerebral hemorrhage complicated with pulmonary infection, has obvious advantages compared with simple western medicine treatment, and can effectively relieve clinical symptoms of patients.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating cerebral hemorrhage complicated with pulmonary infection and a preparation method thereof.
Background
Cerebral hemorrhage (intracerebral hemorrhage, ICH) is hemorrhage caused by rupture of blood vessels in primary non-traumatic brain parenchyma, also called spontaneous cerebral hemorrhage, and has high mortality, high disability rate and high readmission rate. With data statistics, only 6 patients can survive every 10 patients within 1 month after ICH onset, and the death rate in the acute phase is 30-40%. The occurrence rate of pulmonary infection in the diagnosis and treatment process is high, and the disease is one of the most common and serious complications and one of the causes of death of ICH patients finally. The clinical importance of patients with cerebral hemorrhage complicated with pulmonary infection is high, and the western medicine treatment of the disease is to choose sensitive antibiotics, although the curative effect is considerable, the drug resistance is easy to generate after long-term use, so that the symptoms of the patients are not obviously improved after the high-level antibiotics are applied to treat, the curative effect is inhibited, and the prognosis of the disease is adversely affected. The traditional Chinese medicine can improve the symptoms of patients by conditioning the internal environment of the human body, so that the Western medicine differentiation disease can be combined with the dialectical of the traditional Chinese medicine at the present stage, and the result shows that the method can reduce the drug resistance and has higher safety by adopting the combined therapy of the traditional Chinese medicine and the Western medicine.
Disclosure of Invention
Aiming at the problems, the invention aims to provide the traditional Chinese medicine composition for treating cerebral hemorrhage complicated with pulmonary infection and the preparation method thereof, and the traditional Chinese medicine composition can be matched with western medicine conventional treatment to treat cerebral hemorrhage complicated with pulmonary infection patients, has obvious advantages compared with simple western medicine treatment, and can effectively relieve clinical symptoms of patients.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection is characterized by comprising the following components: astragalus root, pilose asiabell root, largehead atractylodes rhizome, indian buead, baical skullcap root, common anemarrhena rhizome, white mulberry root-bark, thunberg fritillary bulb, prepared pinellia tuber, tangerine peel, snakegourd seed, apricot seed, raw rhubarb, officinal magnolia bark, immature bitter orange and liquoric root;
the weight portions of the different components are as follows: 15-25 parts of astragalus membranaceus, 10-20 parts of codonopsis pilosula, 10-20 parts of bighead atractylodes rhizome, 10-15 parts of poria cocos, 10-15 parts of scutellaria baicalensis, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of cortex mori, 8-12 parts of fritillaria thunbergii, 10-15 parts of rhizoma pinellinae praeparata, 10-15 parts of pericarpium citri reticulatae, 4-8 parts of semen trichosanthis, 4-8 parts of almond, 6-12 parts of raw rheum officinale, 10-15 parts of magnolia officinalis, 5-15 parts of immature bitter orange and 4-8 parts of liquorice.
Preferably, the parts by weight of the different components are respectively as follows: 20 parts of astragalus, 15 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 12 parts of poria cocos, 12 parts of scutellaria baicalensis, 12 parts of rhizoma anemarrhenae, 12 parts of white mulberry root-bark, 9 parts of fritillaria thunbergii, 12 parts of rhizoma pinellinae praeparata, 12 parts of dried orange peel, 6 parts of semen trichosanthis, 6 parts of almond, 9 parts of raw rhubarb, 12 parts of magnolia officinalis, 10 parts of immature bitter orange and 6 parts of liquorice.
The pharmacology of each component is as follows:
radix astragali: sweet and slightly warm. It enters lung, spleen, liver and kidney meridians. Qi-tonifying, exterior-strengthening, sweat-arresting, sore-supporting, tissue-promoting, diuresis-inducing and detumescence;
radix codonopsis pilosulae: sweet and flat. Enter spleen and lung meridians. Tonifying middle-jiao and Qi, harmonizing stomach, promoting fluid production, eliminating phlegm and relieving cough;
white atractylodes rhizome: bitter, sweet and warm. Enter spleen and stomach meridians. Tonifying qi and strengthening spleen, drying dampness and promoting diuresis, stopping sweat and preventing miscarriage;
poria cocos: sweet, light and flat. It enters heart, lung and spleen meridians. Excreting dampness and promoting diuresis, strengthening spleen and stomach, calming heart and tranquilizing mind;
radix Scutellariae Baicalensis: bitter and cold. It enters lung, gallbladder, spleen, large intestine and small intestine meridians. Clearing heat and drying dampness, purging fire and detoxicating, stopping bleeding and preventing abortion;
rhizoma anemarrhenae: bitter and cold. It enters lung, stomach and kidney meridians. Nourishing yin, reducing pathogenic fire, moistening dryness and smoothing intestine;
cortex Mori: sweet and cold. Enter lung meridian. Purging lung, relieving asthma, inducing diuresis to alleviate edema;
thunberg fritillary bulb: bitter and cold. It enters heart and lung meridians. Clearing heat and resolving phlegm, resolving masses and detoxifying;
rhizoma Pinelliae Preparata: pungent and warm. Enter spleen, stomach and lung meridians. Drying dampness and resolving phlegm;
dried orange peel: pungent and bitter, warm. Enter spleen and lung meridians. Regulating qi-flowing, invigorating stomach, eliminating dampness, resolving phlegm, lowering adverse qi, relieving vomiting, dispersing stagnated liver qi, and activating qi-flowing;
semen trichosanthis: sweet, slightly bitter and cold. Enter lung, stomach and large intestine meridians. Clearing heat and resolving phlegm, relieving chest stuffiness and resolving masses, and relaxing bowel;
and (3) almond: bitter and slightly warm. Enter the lung and large intestine meridians. Relieving cough and asthma, and loosening bowel to relieve constipation;
raw rhubarb: bitter and cold. Enters the stomach and large intestine. Removing stagnation, clearing damp-heat, purging pathogenic fire, cooling blood, removing blood stasis, and removing toxic substances;
cortex Magnoliae officinalis: bitter, pungent and warm. Enter spleen, stomach, lung and large intestine meridians. Drying dampness, resolving phlegm, descending qi and removing fullness;
immature bitter orange: bitter, pungent and slightly acidic, slightly warm. Enter spleen and stomach meridians. Breaking qi, removing food retention, resolving phlegm and dispersing masses;
licorice root: sweet and flat. It enters heart, lung, spleen and stomach meridians. Spleen invigorating, qi replenishing, heat and toxic materials clearing away, phlegm eliminating, cough relieving, pain relieving, and medicines regulating.
Further, the preparation method of the traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection is characterized by comprising the following steps:
s1: weighing radix astragali, radix Codonopsis, atractylodis rhizoma, poria, scutellariae radix, rhizoma anemarrhenae, cortex Mori, bulbus Fritillariae Thunbergii, rhizoma Pinelliae Preparata, pericarpium Citri Tangerinae, semen Trichosanthis, semen Armeniacae amarum, radix et rhizoma Rhei, cortex Magnolia officinalis, fructus Aurantii Immaturus and Glycyrrhrizae radix, placing into a marmite, adding cold water to 3-5cm above the medicinal materials, soaking for 30 min, boiling with strong fire, decocting with slow fire for 30 min, and filtering to obtain primary filtrate;
s2: adding 0.9-1L warm water into the marmite, continuously boiling with strong fire, decocting with slow fire for 30 min, and filtering to obtain secondary filtrate;
s3: mixing the primary filtrate and the secondary filtrate, and heating and concentrating to 400 ml.
The beneficial effects of the invention are as follows: compared with the prior art, the invention has the advantages that,
the traditional Chinese medicine composition provided by the invention is prepared from astragalus, codonopsis pilosula, bighead atractylodes rhizome, poria cocos, radix scutellariae, rhizoma anemarrhenae, cortex mori, fritillaria thunbergii, rhizoma pinellinae praeparata, dried orange peel, semen trichosanthis, almond, raw rheum officinale, magnolia officinalis, immature bitter orange and liquorice. In the formula, astragalus root, pilose asiabell root, white atractylodes rhizome and honey-fried licorice root warm middle-jiao and invigorate spleen and tonify qi of spleen and stomach; zhi mu and Zhe Bei mu are bitter and cool, and Gua Lou ren is sweet and cold in nature, and are good at clearing heat and resolving phlegm; rhizoma Pinelliae Preparata is matched with Scutellariae radix for dispelling phlegm, resolving masses, clearing heat and lowering fire; for phlegm, it is necessary to lower the fire, while the bark of white mulberry clears away the lung fire; for fire, bitter apricot kernel is used for reducing and promoting the flow of lung qi to disperse upwards, dried orange peel is used for regulating qi and resolving phlegm to smooth middle-jiao, and poria cocos is used for strengthening spleen and excreting dampness to Du Shengtan; rhubarb is bitter and cold, has the functions of purging heat and promoting the circulation of the intestines, cooling blood and removing toxin, and removing blood stasis and promoting menstrual flow; magnolia officinalis and fructus Aurantii Immaturus are effective in activating qi-flowing and dispersing full; the combination of the medicines can strengthen the spleen, resolve phlegm, clear heat, regulate qi and purgate, and the combination of the purgation and the purgation can remove all symptoms. The traditional Chinese medicine composition can be matched with western medicine conventional treatment to treat patients with cerebral hemorrhage complicated with pulmonary infection, and western medicine differentiation disease is combined with traditional Chinese medicine dialectical, so that compared with simple western medicine treatment, the traditional Chinese medicine composition has more obvious advantages, can effectively relieve clinical symptoms of patients, and is worthy of popularization and application.
Drawings
Fig. 1 is a CT photograph of a pre-treatment chest of a typical case 8 Liu of the present invention.
Fig. 2 is a chest CT photograph of a typical case of the present invention taken after a certain treatment of 8 u.
Fig. 3 is a CT photograph of a pre-treatment chest of a horse of example 10 of the present invention.
Fig. 4 is a chest CT photograph of a typical case 10 horse of the present invention taken after a certain treatment.
Fig. 5 is a CT photograph of a pre-treatment chest of a typical case 12 horse of the present invention.
Fig. 6 is a chest CT photograph of a typical case 12 horse of the present invention taken after a certain treatment.
Detailed Description
In order to enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention is further described below with reference to the accompanying drawings and examples.
A traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection comprises the following components: astragalus root, pilose asiabell root, largehead atractylodes rhizome, indian buead, baical skullcap root, common anemarrhena rhizome, white mulberry root-bark, thunberg fritillary bulb, prepared pinellia tuber, tangerine peel, snakegourd seed, apricot seed, raw rhubarb, officinal magnolia bark, immature bitter orange and liquoric root;
the weight portions of the different components are as follows: 20 parts of astragalus, 15 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 12 parts of poria cocos, 12 parts of scutellaria baicalensis, 12 parts of rhizoma anemarrhenae, 12 parts of white mulberry root-bark, 9 parts of fritillaria thunbergii, 12 parts of rhizoma pinellinae praeparata, 12 parts of dried orange peel, 6 parts of semen trichosanthis, 6 parts of almond, 9 parts of raw rhubarb, 12 parts of magnolia officinalis, 10 parts of immature bitter orange and 6 parts of liquorice.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
weighing radix astragali, radix Codonopsis, atractylodis rhizoma, poria, scutellariae radix, rhizoma anemarrhenae, cortex Mori, bulbus Fritillariae Thunbergii, rhizoma Pinelliae Preparata, pericarpium Citri Tangerinae, semen Trichosanthis, semen Armeniacae amarum, radix et rhizoma Rhei, cortex Magnolia officinalis, fructus Aurantii Immaturus and Glycyrrhrizae radix, placing into a marmite, adding cold water to 3-5cm above the medicinal materials, soaking for 30 min, boiling with strong fire, decocting with slow fire for 30 min, and filtering to obtain primary filtrate;
s2: adding 0.9-1L warm water into the marmite, continuously boiling with strong fire, decocting with slow fire for 30 min, and filtering to obtain secondary filtrate;
s3: mixing the primary filtrate and the secondary filtrate, and heating and concentrating to 400 ml.
Further, the animal experiment is carried out on the traditional Chinese medicine composition, and the specific contents include:
1. animal test study:
1.1 Chinese medicinal composition
20g of astragalus, 15g of codonopsis pilosula, 15g of bighead atractylodes rhizome, 12g of poria cocos, 12g of radix scutellariae, 12g of rhizoma anemarrhenae, 12g of cortex mori, 9g of fritillaria thunbergii, 12g of rhizoma pinellinae praeparata, 12g of dried orange peel, 6g of semen trichosanthis, 6g of almond, 9g of raw rheum officinale, 12g of magnolia officinalis, 10g of immature bitter orange and 6g of liquorice.
1.2 preparation of Chinese medicinal composition
The decoction is carried out according to the conventional decoction method of traditional Chinese medicine until the maximum concentration is reached, namely the concentration which can not cause the change of pharmacological properties just through a forced feeding needle head, the final concentration is 4.92g/ml, and the decoction is stored in a refrigerator at 4 ℃.
1.3 grouping and intervention of test animals
60 Kunming mice were purchased randomly into 4 groups, a blank control group, a low, medium, and high dose group, respectively. 15 animals in each group, the male and female are not restricted. Mice were fasted for 12 hours without water control prior to the experiment and were gavaged at 0.4ml/10g body weight 2 times daily with 8 hours intervals. The blank group is prepared from normal saline with the same volume, and the low dose group, the medium dose group and the high dose group are respectively 98.4g/kg,196.8g/kg and 393.6g/kg, which are respectively 48 times, 96 times and 192 times of the clinical daily dose of the adult. The behavioral response of the mice was observed immediately after gastric lavage, once daily, for 14 days.
1.4 observations index
1.4.1 daily observations of mice behaviour, changes in coat, diet, eye and mucous membrane, changes in respiration, defecation, secretions and the like, as well as toxic and dead conditions.
1.4.2 on day 14 post-administration, mice were tested for hematology indicators, total Red Blood Cells (RBC), total White Blood Cells (WBC), platelet count ((PLT), hemoglobin (Hb), etc.
1.4.3 on day 14 after administration, biochemical indicators of serum aspartate Aminotransferase (AST), serum alanyl transferase (ALT), urea nitrogen (BUN), serum creatinine (Cr) and the like were measured.
1.5 statistical analysis
The SPSS 24.0 software was used, one-way analysis of variance ((ANOVA), data expressed as mean ± standard deviation (x±s), with p <0.05 as the standard for significant differences.
1.6 results
1.6.1 general State observations in mice
The mice were less active, calm, reduced diet, and no other abnormal reactions were seen in the first day of dosing, mice were free to move, normal in appearance, normal in diet, increased body weight, normal in urination, no abnormal secretions, no toxic reactions and no death from the second day to the end of the experiment. There were no significant differences in the weight comparisons of the mice in the groups prior to the experiment, and no statistical differences (p > 0.05) in the weight comparisons of the mice in the groups after the experiment, as shown in Table 1 below:
1.6.2 results of the detection of the hematology index of mice
The hematological index of each group of mice after the end of administration was within the normal range, and there was no significant difference (p > 0.05) between each group of administration and the blank group, and no statistical difference (p > 0.05) between each group of administration, as shown in table 2 below:
TABLE 2 statistical results of acute toxicity test of blood cell components of mice with the formulation
1.6.3 detection results of various indexes of blood biochemistry of mice
No obvious abnormality was observed in the blood biochemical index of each group of mice after the end of administration, no obvious difference was observed between each administration group and the blank group (p > 0.05), and no statistical difference was observed between each administration group (p > 0.05), as shown in table 3 below:
Furthermore, the traditional Chinese medicine composition is used for treating cerebral hemorrhage combined with pulmonary infection by combining with Western medicine, and has good clinical effect, and specific clinical experiments are reported below.
2. Clinical report:
2.1 general data
72 patients who are received from affiliated hospitals of Chinese medicine university in Shaanxi and diagnosed with cerebral hemorrhage and pulmonary infection in the period of 12 months in 2020-2021 are selected as observation objects. They were divided into 36 cases in the control group and the treatment group by the random number table method. In the treatment group, 23 men and 13 women, age 46-80 years, average (60.47+ -5.03) years, lung infection course 1-6 hours, average (4.03+ -0.89) hours, bleeding site: 22 cases of basal ganglia hemorrhage, 7 cases of ventricular hemorrhage, 5 cases of thalamus hemorrhage and 2 cases of brainstem hemorrhage; in the control group, 21 men and 15 women, age 44-79 years, average (59.58+ -4.07) years, lung infection course 1-6 hours, average (3.98+ -0.76) hours. Bleeding site: 21 cases were basal ganglia hemorrhage, 9 cases were ventricular hemorrhage, 5 cases were thalamus hemorrhage, and 1 case was brainstem hemorrhage. The two groups of patients have no statistical significance (P is more than 0.05) in comparison with common data such as gender, age, lung infection course, bleeding position and the like, and are comparable. See table 4 below. The study meets the relevant requirements of the declaration of Helsinki of the world medical society.
Table 4 general data survey and analysis of two groups of cerebral hemorrhage combined with pulmonary infection patients
2.2 diagnostic criteria
Western diagnostic criteria: the cerebral hemorrhage diagnosis is formulated by referring to China cerebral hemorrhage diagnosis and treatment Specification in 2019; the lung infection diagnosis refers to clinical diagnosis standard of the apoplexy-related pneumonia in 2019, china expert consensus for diagnosis and treatment of the apoplexy-related pneumonia.
Diagnostic criteria for traditional Chinese medicine: referring to the guidelines of clinical research on new traditional Chinese medicines and the standards of diagnostic curative effects of traditional Chinese medicine symptoms, the main symptoms are fever, cough, expectoration, chest pain, chest distress and the like, and the secondary symptoms include yellow urine, abdominal distention, constipation, polydipsia, red tongue with yellow coating and slippery and rapid pulse.
Inclusion criteria
(1) Age 40-80 years old, unlimited in sex; (2) Meets the diagnosis standard of the cerebral hemorrhage acute phase and the cerebral hemorrhage convalescence phase; (3) meets the diagnosis criteria for stroke-related pneumonia; (5) accords with the diagnosis standard of the phlegm-heat accumulated lung syndrome in the traditional Chinese medicine; (6) The patient or family member is informed consent and signed.
2.3 exclusion criteria
Potential subjects meeting inclusion criteria will be excluded if any of the following are met:
(1) There are infections at other sites than the pulmonary infection; (2) bleeding due to brain trauma or brain tumor stroke; (3) non-primary cerebral hemorrhage; (4) a history of infection half a month before stroke; (5) Serious primary diseases such as heart, lung, liver, kidney, hematopoietic system and endocrine are combined; (6) combining mental abnormalities, pregnant or lactating women; (7) cachexia, allergic constitution; (8) being attended by other researchers; (9) other traditional Chinese medicines are taken simultaneously.
2.4 method
After two groups of patients are admitted, the patients are divided into 36 cases of an observation group and a control group by adopting a random digital table method, wherein the control group is treated by adopting the conventional western medicines in the hospital, and the main treatment method is to control the blood pressure and the blood sugar of the patients, reduce intracranial pressure, nourish brain nerves, maintain electrolyte and acid-base balance and the like, and simultaneously, the patients are subjected to anti-infection, sputum drainage, aerosol inhalation, related support treatment and the like. The observation group is treated by adding the traditional Chinese medicine composition in the first embodiment to the treatment of the basic western medicines of the control group, wherein the nasal feeding administration is carried out on patients with dysphagia, the prescription comprises 20g of astragalus, 15g of codonopsis pilosula, 15g of bighead atractylodes rhizome, 12g of poria cocos, 12g of scutellaria baicalensis, 12g of rhizoma anemarrhenae, 12g of cortex mori radicis, 9g of fritillaria thunbergii, 12g of rhizoma pinellinae praeparata, 12g of pericarpium citri reticulatae, 6g of semen trichosanthis, 6g of almond, 9g of raw rheum officinale, 12g of magnolia officinalis, 10g of immature bitter orange and 6g of liquorice, and the nasal feeding is carried out according to symptoms, 1 dose/d is formed, and 400mL of decoction is taken for 2 times in the morning and evening. The treatment course is 14d.
2.5 observations index
2.5.1 evaluation of therapeutic efficacy of Chinese medicine
Judging the curative effect of the traditional Chinese medicine syndrome of a patient, and specifically referring to the principles of clinical guidelines for new traditional Chinese medicine: efficacy index = (pre-treatment score-post-treatment score)/pre-treatment score x 100%; clinical control: the clinical manifestation disappears or the clinical manifestation is not obvious, and the score level is reduced by more than or equal to 90 percent; the effect is shown: the clinical manifestation is obviously relieved, but partial clinical manifestation is not improved, and the grading level is reduced by more than or equal to 70%; the method is effective: the clinical manifestations are relieved, but the degree is not obvious, and the score is reduced by more than or equal to 30 percent; invalidation: clinical manifestations were not relieved or progressive aggravated with a score decrease of < 30%. Total effective rate= (number of clinical control cases + number of significant cases + number of effective cases)/36×100%.
2.5.2 evaluation of pulmonary infection efficacy
Clinical pulmonary infection assessment criteria clinical pulmonary infection scoring table (CPIS) was referenced to assess pulmonary infection before and after cerebral hemorrhage in time. Clinical Pulmonary Infection Score (CPIS), which includes clinical manifestations, imaging and microbiological criteria, is a scoring system used to assess the severity of infection, and includes blood white count, body temperature, tracheal secretions, chest radiographs, oxygenation index [ partial oxygen pressure (PaO) 2 ) Concentration of inhaled oxygen (FiO) 2 )]And (5) comprehensive scoring of the indexes.
2.5.3 inflammation index
Pre-treatment and post-treatment white blood cell counts (WBCs), C-reactive protein (CRP), procalcitonin (PCT) were detected and recorded for both groups of patients, all tested by the laboratory department.
2.5.4 clinical symptom improvement cases
And observing and recording cough vanishing time, lung wetting sound vanishing time, body temperature recovery normal time and WBC recovery normal time of the two groups of patients in the treatment process.
2.5.5 Security comparison
Adverse reactions were observed, and whether there was abnormality in blood-urine routine, liver-kidney function, and electrocardiogram was observed in both groups of patients after treatment.
2.6 statistical methods
The data were all statistically analyzed using SPSS23.0 software. Count data expressed as percent (%), inter-group row χ2 test; the measurement data are represented by mean value +/-standard deviation (+/-s), and conform to data with normal distribution and uniform variance, such as measurement data of symptom vanishing time, lung infection index, inflammation index and the like, and the inter-group line independent sample t test and the intra-group line paired t test; p <0.05 indicates that the difference is statistically significant.
2.7 results
2.7.1 comparison of clinical efficacy of traditional Chinese medicine for two groups of patients
The total effective rate of the treatment group is 91.67%, which is higher than 80.56% of the control group, and the comparison difference has statistical significance (P < 0.05). See table 5 below.
Table 5 comparison of clinical efficacy of traditional Chinese medicine for two groups of patients [ example (%)
Note that: p <0.05 compared to the control group.
2.7.2 comparison of CPIS, WBC, CRP, PCT indicators before and after treatment of two groups of patients
There was no significant difference (P > 0.05) in CPIS scores from blood WBC, CRP, PCT comparisons for both groups of patients prior to treatment; after treatment 7d, 14d, both groups of patients had a decrease in CPIS score and blood WBC, CRP, PCT (P < 0.05), and the treatment group decreased more significantly (P < 0.05). See table 6 below.
Note that: p <0.05 compared to control after treatment; ΔP <0.05 compared to before and after treatment in the same group.
2.7.3 comparison of time to improvement of clinical symptoms in two groups of patients
The cough vanishing time, lung wetting sound vanishing time, body temperature recovery normal time and WBC recovery normal time after treatment of the treatment group are shorter than those of the control group, and the difference has statistical significance (P < 0.05). See table 7 below.
Note that: p <0.05 compared to the control group.
2.7.4 comparison of adverse effects of treatment for two groups of patients
No obvious adverse reaction such as vomit is seen in the two groups of patients during the treatment period, and no obvious abnormal manifestation of hematuria, liver and kidney functions and electrocardiogram is seen in the treatment process.
2.8 discussion
Modern pharmacological researches have proved that the pinellia acid component in pinellia tuber has the effects of inhibiting airway allergic reaction, relieving cough and asthma, eliminating phlegm and regulating gastrointestinal function, inhibiting thrombosis, preventing coagulation factor from being exhausted, improving blood rheology and the like; the baicalin in the baikal skullcap root can inhibit the formation of bacterial biofilm, can enhance the damage effect of antibiotics on the biofilm, and has researches indicate that the baikal skullcap root has obvious inhibition effect on pseudomonas aeruginosa, staphylococcus aureus and the like; the main pharmacological effects of the dried orange peel are eliminating phlegm and resisting inflammation, and relieving collagen deposition and inflammatory reaction in lung tissues of mice; the polysaccharide component in the poria cocos can enhance the immune response of organisms and has an obvious inhibiting effect on the toxic effect of klebsiella pneumoniae; the rheum officinale can relieve neurological deficit, promote edema to subside and inhibit inflammatory factor level in cerebral hemorrhage treatment; the rhodiola rosea has the basic pharmacological effects of improving nerve injury after cerebral hemorrhage, reducing nerve cell necrosis and apoptosis, resisting inflammation and oxidization, inhibiting inflammatory factor expression and protecting pulmonary vascular permeability; the herba Patriniae extract has antibacterial and antiinflammatory effects, and can inhibit Pseudomonas aeruginosa; the saponins in radix Platycodi have effects of relieving cough and asthma and resisting lung injury; the active ingredients in the liquorice have anti-inflammatory effect, can inhibit the expression of inflammatory mediators, and have better functions of relieving cough and eliminating phlegm.
The clinical study shows that after the conventional Western medicine treatment is combined with the prescription for strengthening spleen, purging lung and relaxing viscera, the total clinical effective rate of the treatment group is obviously higher than that of the control group; the clinical lung infection scores and serum inflammatory factor levels of the two groups after treatment are reduced compared with those before treatment, and the difference has statistical significance (P is less than 0.05) compared with the difference before treatment, so that the reduction of the treatment group is more remarkable; the cough vanishing time, lung wetting sound vanishing time, body temperature recovery normal time and WBC recovery normal time after treatment of the treatment group are shorter than those of the control group, and the difference has statistical significance (P is less than 0.05). The results show that the traditional Chinese medicine composition for treating cerebral hemorrhage complicated with pulmonary infection can obviously improve the treatment effect, reduce the serum inflammatory factor level, shorten the disappearance time of clinical symptoms, improve symptoms and signs, effectively control the disease development and promote the rehabilitation of patients.
In conclusion, the traditional Chinese medicine composition is used for treating cerebral hemorrhage complicated with pulmonary infection on the basis of western medicine treatment, has remarkable curative effect, can improve clinical treatment effect, effectively reduces serum inflammatory factor level, fully plays the advantages of combining traditional Chinese medicine and western medicine for treating the disease, controls disease development, and has higher clinical application value.
Typical cases:
1. guo Mou Ind for 6 hours, ind for complaints, CT for cranium and chest: subarachnoid hemorrhage and bruising. Mild interstitial changes in both lungs; the pleura on both sides thicken. Lung infection was secondary 6 days after admission, chest CT showed: double lung multiple streaks, considering inflammation, increased in range over the anterior. After 2 courses of treatment, the patient expectoration and fever symptoms are relieved, and chest CT is reviewed: the multiple streaks of the two lung are absorbed obviously. The lung infection is obviously controlled.
2. Some men, 75 years old, found confusion with vomiting for more than 16 hours as complaints for admission, admission for craniocerebral and chest CT presentation: left frontal lobe and temporal lobe brain contusion and laceration with bleeding; left frontotemporal top subdural hematoma; subarachnoid hemorrhage. The leaf-falling and accumulation of the two lung-falling diseases are changed; double pneumonia exudes. After the traditional Chinese medicine composition is taken for 3 courses of treatment, the symptoms of expectoration and fever of patients are relieved, and chest CT is reviewed to show: the range of the lesion of the lower lobes of the two lungs is reduced more than the anterior one. Pulmonary infection control.
3. For some, men, 55 years old, left limb dyskinesia caused by cerebral hemorrhage is treated as a complaint for admission to the hospital, and for admission to craniocerebral and chest CT shows: the right parietal occipital lobe had cerebral hemorrhage (hemorrhage amount about 50 ml) and was secondary to a sickle-brain hernia. Chronic bronchitis, emphysema, lung bulla. The two lung powder is scattered on nodular and chordae focus, and pulmonary tuberculosis. In combination with clinical and other related examinations. Postoperative lung infection, chest CT shows: chronic bronchitis, emphysema, lung bulla, are generally the same as before. The two lungs are multiple nodular and chordae focus, approximately the same as before. After 2 courses of treatment, the patient expectoration and fever symptoms are relieved, and chest CT is reviewed: chronic bronchitis and emphysema. Pulmonary infection control.
4. Some of these plums, men, 48 years old, 3 hours of sudden unconsciousness were complained for admission to the hospital, for admission to craniocerebral and chest CT shows: left basal ganglia cerebral hemorrhage with hemorrhage amount of about 27ML, brain swelling, secondary mild cerebral herniation; left lung lower lobe lung blood is stagnant. Lung infection was secondary 6 days after admission, chest CT showed: the inflammation of the lower lobes of the two lungs is obvious before. After taking the traditional Chinese medicine composition for 3 courses of treatment, the expectoration and fever symptoms of patients are relieved, and the chest CT is reviewed: lower lobe inflammation of the two lungs, right small amount of pleural effusion, decreased than before. Pulmonary infection control.
5. Some horses, women, 72 years old, sudden confusion for 2 hours are complaints of admission to the hospital, admission to the craniocerebral and chest CT shows: cerebral hemorrhage (30 ml) in the basal region of the right side breaks into the ventricles of the side with herniation of the lower brain sickle. The lung interstitium proliferates. Chronic inflammation of the middle lobe of the right lung and tongue lobe of the left lung is accompanied by chordae focus. After 6 courses of treatment of postoperative administration of the traditional Chinese medicine composition provided by the invention, the symptoms of expectoration and fever of patients are relieved, and chest CT is reviewed: the inflammation of the lung is relieved before the lung is scattered. The lung infection is obviously controlled.
6. Some women, 54 years old, headache, dizziness with blurred vision of the right eye for 3 months are complained to admix, admix to check craniocerebral MR and chest CT show: the right parasaddle meningioma is accompanied by a sickle herniation of the brain surrounding the right internal carotid artery and middle cerebral artery. Consider the right top small meningioma. Middle lobe and lower lobe foci of right lung, chronic inflammatory fibrochordae foci. Lung infection was secondary 4 days post-surgery, chest CT shows: two lung infectious lesions, a small amount of effusion in the chest on both sides. After 2 courses of treatment, the patient expectoration and fever symptoms are relieved, and chest CT is reviewed: the upper lobe inflammation of the left lung is absorbed earlier. The lung infection is obviously controlled.
7. Some women, 57 years old, sudden confusion with left limb movement disorder 20 days are complained to admix, admix to check craniocerebral and chest CT show: peripheral oedema is remarkable in the right basal segment cerebral hemorrhage absorption period. Left lung lower lobe inflammation, bilateral pleural effusion. After 2 courses of treatment, the patient expectoration and fever symptoms are relieved, and chest CT is reviewed: the inflammation of the lower lobe of the original left lung and bilateral small amount of pleural effusion are absorbed this time. The lung infection is obviously controlled.
8. Some Liu, a man, age 81, 4 hours of sudden consciousness is a complaint of admission to the hospital, a check of cranium and chest CT showing: the right basal ganglia cerebral hemorrhage (hemorrhage amount about 28 ml) breaks into the ventricular system. Basal segment localized inflammation in the lower lobe of the right lung. Pulmonary infection was aggravated 7 days after surgery, chest CT (as shown in fig. 1) showed: the range of the leaf spot shadow under the two lungs is further increased than the former. The pleural effusion is small at two sides, and the amount is increased more than before. After taking the traditional Chinese medicine composition for 3 courses of treatment, the expectoration and fever symptoms of the patient are relieved, and the chest CT (shown in the figure 2) is reviewed: the lower lobe of the two lungs and the upper lobe of the right lung are high-density shadows, which are smaller than the former range. The lung infection is obviously controlled.
9. Some women in the field, 71 years old, sudden unconsciousness for 3 hours is a complaint admission, postoperative chest CT shows: inflammation of the two lungs. After 2 courses of treatment, the patient expectoration and fever symptoms are relieved, and chest CT is reviewed: inflammation of both lungs is absorbed earlier. And the lung infection is effectively controlled.
10. Some horses, men, 63 years old, had sudden right limb movement disorder with speech impairment for more than 4 hours were complained to admix, admix to check cranium and chest CT (as shown in fig. 3) showing: left basal ganglia cerebral hemorrhage (amount about 5.5 ml). The lower lobe plaque of the double lung is a high-density shadow, which is marked on the right side, and the falling-accumulation type pneumonia is considered. After 4 treatment courses of taking the traditional Chinese medicine composition provided by the invention, the expectoration and fever symptoms of a patient are reduced, and the chest CT (shown in figure 4) is reviewed: the two lung inflammations are better. And the lung infection is effectively controlled.
11. Some men, 60 years old, complaints with unconsciousness for more than 1 hour are mainly complaints to be admitted, and admission to craniocerebral and chest CT shows: brainstem bleeding, with a bleeding volume of about 3ml. Changes in the interstitium of the two lungs and effects of the deposition. 13 days of admission secondary to pulmonary infection, chest CT shows: the lung is scattered in inflammation. After taking the traditional Chinese medicine composition for 3 courses of treatment, the expectoration and fever symptoms of patients are relieved, and the chest CT is reviewed: the lung is better than the lung in inflammation. And the lung infection is effectively controlled.
12. Some horses, 73 years old, had weak right limb strength, vague speech and a left skew of the mouth for 3 hours were complaints for admission to the hospital, and admission to the craniocerebral and thoracic CT (as shown in fig. 5) showed: left frontal temporal lobe cerebral hemorrhage (hemorrhage amount about 32 ml), local rupture into subarachnoid space. The tongue section of the upper left lung and the lower two lung are inflammatory. After taking the traditional Chinese medicine composition for 3 courses of treatment, the expectoration and fever symptoms of the patient are reduced, and the review of chest CT (shown in figure 6) shows that: the inflammation of the lower lobes of the two lungs is relieved before the anterior inflammation. The patch-shaped compact shadow in the original trachea cavity is absorbed. The lung infection is obviously controlled.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made without departing from the spirit and scope of the invention, which is defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (3)
1. A traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection is characterized by comprising the following components: astragalus root, pilose asiabell root, largehead atractylodes rhizome, indian buead, baical skullcap root, common anemarrhena rhizome, white mulberry root-bark, thunberg fritillary bulb, prepared pinellia tuber, tangerine peel, snakegourd seed, apricot seed, raw rhubarb, officinal magnolia bark, immature bitter orange and liquoric root;
the weight portions of the different components are as follows: 15-25 parts of astragalus membranaceus, 10-20 parts of codonopsis pilosula, 10-20 parts of bighead atractylodes rhizome, 10-15 parts of poria cocos, 10-15 parts of scutellaria baicalensis, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of cortex mori, 8-12 parts of fritillaria thunbergii, 10-15 parts of rhizoma pinellinae praeparata, 10-15 parts of pericarpium citri reticulatae, 4-8 parts of semen trichosanthis, 4-8 parts of almond, 6-12 parts of raw rheum officinale, 10-15 parts of magnolia officinalis, 5-15 parts of immature bitter orange and 4-8 parts of liquorice.
2. The traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection according to claim 1, wherein the traditional Chinese medicine composition comprises the following components in parts by weight: 20 parts of astragalus, 15 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 12 parts of poria cocos, 12 parts of scutellaria baicalensis, 12 parts of rhizoma anemarrhenae, 12 parts of white mulberry root-bark, 9 parts of fritillaria thunbergii, 12 parts of rhizoma pinellinae praeparata, 12 parts of dried orange peel, 6 parts of semen trichosanthis, 6 parts of almond, 9 parts of raw rhubarb, 12 parts of magnolia officinalis, 10 parts of immature bitter orange and 6 parts of liquorice.
3. The method for preparing a traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection according to claim 1 or 2, comprising the following steps:
s1: weighing radix astragali, radix Codonopsis, atractylodis rhizoma, poria, scutellariae radix, rhizoma anemarrhenae, cortex Mori, bulbus Fritillariae Thunbergii, rhizoma Pinelliae Preparata, pericarpium Citri Tangerinae, semen Trichosanthis, semen Armeniacae amarum, radix et rhizoma Rhei, cortex Magnolia officinalis, fructus Aurantii Immaturus and Glycyrrhrizae radix, placing into a marmite, adding cold water to 3-5cm above the medicinal materials, soaking for 30 min, boiling with strong fire, decocting with slow fire for 30 min, and filtering to obtain primary filtrate;
s2: adding 0.9-1L warm water into the marmite, continuously boiling with strong fire, decocting with slow fire for 30 min, and filtering to obtain secondary filtrate;
s3: mixing the primary filtrate and the secondary filtrate, and heating and concentrating to 400 ml.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310155961.9A CN116421679A (en) | 2023-02-23 | 2023-02-23 | Traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310155961.9A CN116421679A (en) | 2023-02-23 | 2023-02-23 | Traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116421679A true CN116421679A (en) | 2023-07-14 |
Family
ID=87080423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310155961.9A Pending CN116421679A (en) | 2023-02-23 | 2023-02-23 | Traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116421679A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111407849A (en) * | 2020-04-13 | 2020-07-14 | 陕西中医药大学附属医院 | Traditional Chinese medicine formula for treating chronic subdural hematoma and preparation method thereof |
-
2023
- 2023-02-23 CN CN202310155961.9A patent/CN116421679A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111407849A (en) * | 2020-04-13 | 2020-07-14 | 陕西中医药大学附属医院 | Traditional Chinese medicine formula for treating chronic subdural hematoma and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
吕雪莹;: "清金化痰汤合小承气汤治疗脑卒中并肺部感染疗效观察", 北方药学, no. 03, 1 March 2017 (2017-03-01), pages 110 - 111 * |
成向进等: "应用泻肺通腑法治疗老年重症肺炎患者的临床研究", 中国中医急症, vol. 27, no. 10, 15 October 2018 (2018-10-15), pages 1758 - 1760 * |
杜建忠编著: "方剂学", vol. 1, 31 May 1988, 甘肃科学技术出版社, pages: 160 * |
黄永军;刘国成;: "培土生金法预防卒中相关性肺炎临床研究", 山东中医杂志, no. 12, 5 December 2013 (2013-12-05), pages 882 - 883 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102940832B (en) | Medicament for treating chronic bronchitis and preparation method thereof | |
CN112870268A (en) | Medicine for treating acute suppurative tonsillitis of children | |
CN114404538B (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
CN116421679A (en) | Traditional Chinese medicine composition for treating cerebral hemorrhage combined with pulmonary infection and preparation method thereof | |
CN111228367B (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
CN108619427B (en) | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis | |
CN106822300B (en) | Traditional Chinese medicine preparation for removing acne and beautifying face | |
CN108355124A (en) | A kind of Chinese medicine composition that treating Air way mucus hypersecretion and its application | |
CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
CN117244015B (en) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof | |
CN118542906B (en) | A Chinese medicinal composition for improving pulmonary fibrosis and pulmonary nodule, and its preparation method | |
CN116531457B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof | |
CN112773862B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN115645478B (en) | Traditional Chinese medicine composition for treating primary dysmenorrhea and preparation method thereof | |
CN109091646B (en) | Compound traditional Chinese medicine preparation for miscarriage prevention of livestock and preparation method thereof | |
CN105998843A (en) | Traditional Chinese medicine preparation for treating recurring type dental ulcers | |
CN104707124A (en) | Traditional Chinese medicine preparation for treating chronic endometritis | |
CN116808168A (en) | Traditional Chinese medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease | |
CN106806762A (en) | A kind of Chinese medicine preparation for treating many phlegm bronchiectasis and preparation method thereof | |
CN118576673A (en) | Traditional Chinese medicine composition for treating calf viral pneumonia and preparation method and application thereof | |
CN105250786A (en) | Traditional Chinese medicine for treating calf pneumonia | |
CN118320037A (en) | Traditional Chinese medicine composition for clearing lung and relieving asthma, and granular medicine and application thereof | |
CN118021907A (en) | Traditional Chinese medicine composition for treating bronchiectasis with infection and preparation method and application thereof | |
CN118576648A (en) | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof | |
CN117462618A (en) | Composition for treating sepsis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |